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Abstract
Background: Ovarian cancer is one of the most lethal cancers and women with type 2 diabetes (T2D) have even
poorer survival from it. We assessed the prognosis of ovarian cancer in women with type 2 diabetes treated with
metformin, other forms of antidiabetic medication, or statins.
Methods: Study cohort consisted of women with T2D diagnosed with ovarian cancer in Finland 1998–2011. They
were identified from a nationwide diabetes database (FinDM), being linked to several national registers. Patients
were grouped according to their medication in the three years preceding ovarian cancer diagnosis. The Aalen–
Johansen estimator was used to describe cumulative mortality from ovarian cancer and from other causes in
different medication groups. Mortality rates were analysed by Cox models, and adjusted hazard ratios (HR) with
95% confidence intervals (95% CIs) were estimated in relation to the use of different forms of medication. Main
outcome measures were death from ovarian cancer and death from other causes.
Results: During the accrual period 421 newly diagnosed ovarian cancers were identified in the FinDM database. No
evidence was found for any differences in mortality from ovarian cancer or other causes between different
antidiabetic medication groups. Pre-diagnostic use of statins was observed to be associated with decreased
mortality from ovarian cancer compared with no such use (HR 0.72, 95% CI 0.56–0.93).
Conclusions: Our findings are inconclusive as regards the association between metformin and ovarian cancer
survival. However, some evidence was found for improved prognosis of ovarian cancer with pre-diagnostic statin
use, requiring cautious interpretation, though.
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Background
Ovarian cancer (OC) is one of the most lethal cancers,
causing 140,000 deaths annually worldwide [1]. The high
mortality rate is attributed to the fact that women
present with the disease at a late stage, as the symptoms
are unspecific and do not emerge until the cancer is ad-
vanced [2]. Standard treatment includes cytoreductive
surgery and adjuvant chemotherapy with platinum and
taxane-based cytostatics. In early disease, treatment with
chemotherapy can be curative but in advanced ovarian
cancer, most patients will have a recurrent disease within
18 months [3].
Women with type 2 diabetes (T2D) are reported to have
poorer survival from OC compared with those without
T2D [4]. Metformin is a type of oral antidiabetic medication
recommended as first-line treatment in T2D [5]. In some
previous studies its use has been linked to favourable sur-
vival in cases of OC [6–8]. Other studies have not been able
to find an association between metformin use and better
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prognosis of OC in women with T2D [4]. The main prob-
lem in previous studies is the small number of patients.
Metformin has anti-mitotic, anti-angiogenic and
anti-inflammatory properties [9]. It inhibits growth of OC
cells in a time- and dose-dependent way, and inhibition is
also seen in platinum-resistant cell lines [10]. Preclinical in
vivo studies have suggested that metformin-treated mice
develop smaller ovarian tumours and fewer metastatic
nodules than controls [11]. It has also been shown that
metformin decreases proliferation of OC cells, decreases
angiogenesis and potentiates the cytotoxic effect of cis-
platin [12].
Patients with T2D have an elevated risk of cardiovascular
diseases and hypercholesterolaemia, and are widely treated
with statins. In Finland, 40% of patients diagnosed with
T2D have been found to use lipid-lowering medication
without diagnosis of coincident coronary heart disease, and
the percentage of medication users increases to 73% in pa-
tients with T2D having coronary heart disease [13]. Statins
(HMG-CoA [3-hydroxy-3-methylglutaryl-CoA] reductase
inhibitors) block formation of cholesterol by inhibiting
HMG-COA conversion to mevalonate [14]. Both in vitro
and in vivo studies indicate that statins have antiprolifera-
tive, proapoptotic, anti-invasive and radio-sensitizing
effects [15].
In most previous reports, OC patients who used statins
showed better overall survival [16–18]. However, in a large
population-based study by Nielsen et al., statin use pre-
dicted reduced cancer-specific mortality among all cancer
patients. No sufficient evidence for improved prognosis
was found when investigating OC patients alone [19].
Also, Habis et al. found no difference between statin users
and non-users as regards OC survival [20].
In the present nationwide register-based cohort study
the associations between use of metformin, other types
of antidiabetic medication and statins, and the prognosis
of OC in patients with T2D was evaluated.
Methods
Study population and design
STROBE guidelines for observational studies were
followed in writing this report [21]. The data on people
with diabetes were collected from a Finnish diabetes
database (FinDM), which combines information from
several nationwide registers including the Care Register
for Health Care and the Finnish Hospital Discharge
Register of the National Institute for Health and Wel-
fare, the Causes of Death Statistics of Statistics Finland
and the Register on Medical Special Reimbursements
and the Register on Reimbursed Drug purchases of the
Social Insurance Institution [22].
The FinDM database includes about 244,000 women with
prevalent (at the beginning of 1996, n = 172,000) or incident
(from 1 January 1996 to 31 December 2011, n = 72,000)
T2D. Persons with diabetes were entered in the FinDM
database if they met at least one of these criteria: diagnosis
of diabetes in some of the used registers (Finnish Health
Care Register, the Hospital Benchmarking database, the
Medical Birth Register, the Diabetes in Finland study or the
Register of Causes of Death) or reimbursement for antidia-
betic medication (ADM) in the register on Reimbursed
Drug purchases of the Social Insurance Institution [22].
The diagnosis of type 2 diabetes is based on World Health
Organization (WHO) criteria in Finland [23]. Data on diag-
noses in hospital records have been available since 1969 for
inpatients and since 1998 for outpatients [22]. Classification
to type 1 (primarily insulin-dependent) and type 2 diabetes
is based on the ADM which was used as the first-line treat-
ment [22]. Good coverage of persons with diabetes was
shown in FinDM when compared with a local diabetes
register covering the Helsinki region [24]. The FinDM data-
base holds information about the quantity and the date of
purchase of all medication prescribed by doctors and reim-
bursed by the Social Insurance Institution, including antidi-
abetic and statin medication, starting from 1994 [22].
From the FinDM database we identified 757 women
who were diagnosed with epithelial ovarian cancer be-
tween 1 January 1998 and 31 December 2011 (Fig. 1).
We excluded those women with a prior cancer diagnosis
(other than non-melanoma skin cancer). We included
women in whom the estimated duration of T2D was at
least 180 days before OC diagnosis. We further excluded
those women whose ovarian cancer were diagnosed at
autopsy. Data on the cancer cases, their histology and
stage were obtained from the Finnish Cancer Registry
(ICD-O-3 [International Classification of Diseases for
Oncology, Third Edition] codes are shown in
Additional file 1) [25]. Stage was categorized as local, ad-
vanced (including growth to adjacent tissues, metastasis
in regional lymph nodes and distant metastasis) or un-
known. The final study cohort contained 421 women
with T2D, who were diagnosed with epithelial ovarian
cancer at least 180 days after the diagnosis of T2D in
1998–2011 (Fig. 1).
Exposure and covariates assessment
Patients were classified into mutually exclusive groups ac-
cording to ADM purchased during the three years before
OC diagnosis: metformin only, other oral ADM only, met-
formin and other oral ADM, insulin at any time and no
history of ADM. Regardless of patients ADM use, they
were also classified as statin users and non-users. The
Anatomical Therapeutic Chemical (ATC) Classification
System was used to define used medication. ATC codes
for different types of oral ADM and statins are shown in
Additional file 2. For all types of medication, exposure was
considered to begin 180 days after the date of purchase. A
patient was classified as a user of ADM when she had
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purchased metformin or other oral ADM for 180 days or
longer in the three years preceding OC diagnosis, with no
history of insulin purchases. If a patient had purchased
oral ADM for less than 180 days, she was classified in the
group “no history of antidiabetic medication”. One pur-
chase of insulin was enough to place the patients in the
“insulin ever” group. Respectively, a patient was classified
as a statin user if she had purchased statin for 180 days or
longer in the three years preceding OC diagnosis. The cu-
mulative use of metformin and statins, respectively, was
estimated by way of defined daily doses (DDDs) purchased
within three years before diagnosis of ovarian cancer.
Outcome ascertainment
Follow-up of the study cohort began at the date of diag-
nosis of ovarian cancer and ended at the time of death,
emigration or closure of the follow-up on 31 December
2011, whichever happened first. Follow-up information
was collected from the Finnish Cancer Registry. By using
personal identity codes, the records of the Finnish Can-
cer Registry are annually matched with those in the
Cause of Death Statistics database, which is maintained
by Statistics Finland. This way, dates and causes of death
(using ICD-10 [International Statistical Classification of
Diseases and Related Health Problems, 10th Revision]
codes) are attached to the records in the Registry.
Personnel at the Finnish Cancer Registry compare the
official causes of death of each patient with diagnosed
cancer with all available data for that cancer, and make a
judgement as to whether the patient died of that cancer
or of something else. The classification of deaths into
the two categories in this study, i.e. deaths from OC and
Fig. 1 Flowchart
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deaths resulting from other causes, was based on that
judgement. Data in the Finnish Cancer Registry is also
linked regularly to the Central Population Register of
Finland to check the correctness of personal identity
codes, complete name, vital status, possible date of death
or emigration and the official place of residence before
the date of diagnosis [26].
Statistical analysis
Mortality from OC and from other causes, respectively,
was assessed in different medication groups by using the
Aalen–Johansen estimator of the cumulative incidence
function for competing risks [27, 28]. Cox proportional
hazards models were fitted for the two causes of death
separately to adjust for the effects of calendar year, age,
duration of T2D, and stage at diagnosis of OC. Hazard ra-
tios (HRs), with accompanying 95% confidence intervals
(CIs) of related to the two causes of death between medi-
cation groups were estimated from the adjusted Cox
models. In supplementary analysis, the medication group
membership indicators in the Cox models were replaced
with cubic spline terms for the total amount of DDDs of
each type of medication purchased [29]. This allowed esti-
mation of a potentially nonlinear dose-dependent effect of
the medications on the mortality from OC. Plots of scaled
Schoenfeld residuals were visually inspected [30], but no
evidence for a violation of the proportional hazards as-
sumption could be observed which would have any impact
on inference. R environment version 3.3.2 was used
throughout for data preparation and statistical analysis;
the Cox models were fitted and assumptions checked with
functions provided in the “survival” package [31, 32].
Results
The age range in the final study cohort (n = 421) was 42
to 92 years at the time of OC diagnosis (Table 1). The
greatest percentage (38%) of ovarian cancers were diag-
nosed at the ages of 70 to 79 years. The majority (78%)
of OC cases were at an advanced stage at the time of
diagnosis. The median duration of follow-up for a pa-
tient was 2.2 years, with a total of 1378 person-years ob-
served in the study.
Eighteen per cent of the OC patients used metformin as
the only antidiabetic drug, 14% used other types of oral
ADM, 24% used metformin combined with other types of
ADM and 19% used insulin (Table 1). A quarter of the
OC patients did not have a history of ADM use. On aver-
age, metformin-only users were younger (median 69 years
Table 1 Distribution of prognostic factors in different medication groupsa
Antidiabetic medication Use of statins
Metforminb Other oral ADMb Metformin and other oral ADMb Insulin No use of ADM Yesb No Total
Number of patients 77 58 100 82 104 186 235 421
Age at diagnosis, years
Median 69 75 70 71 72 71 71 71
IQRc 63─77 66─80 61─77 65─78 64─79 65─77 62─78 64─78
Age categories, years (%)
42─59 8 (10) 6 (10) 19 (19) 9 (11) 17 (16) 18 (10) 41 (17) 59 (14)
60─69 33 (43) 13 (22) 31 (31) 28 (34) 27 (26) 66 (35) 66 (28) 132 (31)
70─79 30 (39) 24 (41) 42 (42) 29 (35) 35 (34) 74 (40) 86 (37) 160 (38)
80─92 6 (8) 15 (26) 8 (8) 16 (20) 25 (24) 28 (15) 42 (18) 70 (17)
Duration of T2D, years (%)
Median 3.1 5.0 6.2 10.8 7.0 6.3 5.7 6.2
IQRc 2.0─5.5 3.1─8.3 4.1─8.9 6.8─15.0 2.0─10.1 3.1─10.0 3.1─10.0 3.1─10.1
0.5─ < 3 37 (48) 15 (26) 13 (13) 4 (5) 34 (33) 45 (24) 58 (25) 103 (24)
3─ < 6 24 (31) 20 (34) 30 (30) 13 (16) 13 (12) 40 (22) 60 (26) 100 (24)
6─ < 12 14 (18) 19 (33) 44 (44) 30 (37) 41 (39) 71 (38) 77 (33) 148 (35)
12─ < 34 2 (3) 4 (7) 13 (13) 35 (43) 16 (15) 30 (16) 40 (17) 70 (17)
Stage (%)
Local 14 (18) 6 (10) 11 (11) 11 (13) 10 (10) 24 (13) 28 (12) 52 (12)
Advanced 58 (75) 45 (78) 77 (77) 64 (78) 86 (83) 142 (76) 188 (80) 330 (78)
Unknown 5 (6) 7 (12) 12 (12) 7 (9) 8 (8) 20 (11) 19 (8) 39 (9)
aThe entries are number and percentages (in parenthesis) if not otherwise stated
bDuration of medication ≥180 days
cInterquartile range
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old) and patients who used other types of oral ADM only
were older (median 75 years old) when compared with pa-
tients in other ADM groups (Table 1). The duration of
diabetes was shorter in the metformin-only group (median
3.1 years) and longer in the insulin group (median
10.8 years) (Table 1). The stage distribution of ovarian
cancer was similar across the ADM groups (Table 1).
One hundred and eighty-six (44%) of the OC patients
were statin users. Statin users and non-users were simi-
lar as regards age distribution, duration of diabetes and
OC stage (Table 1). The most commonly used statins
were lipophilic statins, i.e. simvastatin (56.5% of statin
users) and atorvastatin (26.9%).
Three hundred and ten patients (74%) died during the
follow-up period, most of them (276 patients, 89%) from
ovarian cancer. Unadjusted cumulative mortality from
OC by 10 years after diagnosis varied from 61 to 80%
across the ADM groups and from 69 to 73% between
the groups defined by statin use, whereas the mortality
from other causes by 10 years was on average around
10% with less variability across various ADM and statin
groups (Fig. 2). When adjusted for age, calendar year
and duration of diabetes at diagnosis of OC and for
stage and use of statins, the mortality from OC and from
other causes were not found to differ by ADM (Table 2).
Pre-diagnostic use of metformin as the only treatment
for T2D had an adjusted HR of 1.15 (95% CI 0.74–1.79)
for ovarian cancer death and an adjusted HR of 1.85
(95% CI 0.44–7.73) for death from other causes (Table
2), compared with use of other forms of oral ADM.
Duration of diabetes was not found to be associated with
mortality from ovarian cancer, nor from other causes
(Table 2). Pre-diagnostic use of statin was observed to
predict decreased mortality from ovarian cancer com-
pared with no use of statin (adjusted HR 0.72, 95% CI
0.56–0.93) (Table 2). No sufficient evidence was found
for cumulative use of metformin or statins (DDDs) to be
associated with mortality from OC (Additional file 3).
The results of Cox modelling for the association of
all-cause mortality with ADM and with statins were es-
sentially the same as those for deaths from OC (data not
shown).
Discussion
We found no statistically discernible differences in mor-
tality from ovarian cancer or from other causes between
the groups of ovarian cancer patients with T2D on dif-
ferent types of ADM in the three years before cancer
diagnosis. However, pre-diagnostic use of statin was ob-
served to be associated with an improved prognosis of
OC, but this result must be interpreted with due cau-
tion. To our knowledge, this study is the first one to ex-
plore the association between statin use and ovarian
cancer survival in women with T2D. Our study also has
one of the largest study populations in addressing the re-
lationship between ADM and ovarian cancer survival.
In studies carried out in vitro, statins have shown a
favourable effect on cancer prognosis when combined
with chemotherapy. In human ovarian cancer-cell lines,
synergistic cytotoxicity is seen when combining
Fig. 2 Cumulative incidence function curves of death from OC and from other causes in different groups
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fluvastatin and cisplatin. This has been suggested to be
brought about by dysregulation of Ras-pathway proteins
[33]. Simvastatin is especially cytotoxic when combined
with carboplatin or paclitaxel at higher than physiologic-
ally used concentrations [34].
There are some previous cohort studies on statins and
OC survival. Only two of them did not report a difference
between statin users and non-users [20, 35]. In studies by
Lavie et al. [16], Elmore et al. [17] and Vogel et al. [18],
those ovarian cancer patients who used statins were ob-
served to have better overall survival similarly to our study.
In one of these studies, the suggested favourable effect on
OC survival was seen only with lipophilic statins [18].
In a large population-based Danish study, post-diagnostic
statin use was not found to be related to decreased
all-cause or cancer-specific mortality among ovarian cancer
patients unlike in our study [36]. However, a reduction in
mortality from endometrioid and clear-cell ovarian cancer
subtypes was observed in that study, although the limited
numbers of these rare histological types of OC decreased
the reliability of the results [36]. Mortality was also lower
among those statin users who did not use low-dose aspirin
or had started statin use after OC diagnosis [36]. In our
study registered information on aspirin use was not avail-
able, as in Finland, aspirin is an over-the-counter drug.
The results of some previous studies have suggested
that metformin use is associated with better survival in
cases of ovarian cancer [6–8, 37] unlike in our study,
whereas similarly to our findings, in one study such an
association was not found [38]. The most recent study
on metformin and OC survival also suggested that con-
tinuous use of metformin in women with T2D decreases
Table 2 Estimation results from Cox proportional hazard models of mortality from OC and from other causes
Variable Mortality from OC Mortality from other causes
Group size Deaths HR (95% CI) Deaths HR (95% CI)
Year of diagnosis
1998─2002 115 84 1.00 Ref. 13 1.00 Ref.
2003─2007 149 106 1.17 (0.86–1.59) 12 1.16 (0.45–2.99)
2008─2011 157 86 0.97 (0.69–1.37) 9 1.13 (0.39–3.27)
Age at diagnosis (years)
42─59 59 30 0.67 (0.44–1.04) 1 0.18 (0.02–1.53)
60─69 132 76 1.00 Ref. 9 1.00 Ref.
70─79 160 120 1.53 (1.14–2.05) 14 2.49 (1.03–6.05)
80─92 70 50 2.88 (1.98–4.20) 10 5.40 (1.99–14.65)
Duration of diabetes (years)
0.5─ < 3 103 61 1.00 Ref. 11 1.00 Ref.
3─ < 6 100 70 1.31 (0.91–1.90) 3 0.35 (0.09–1.36)
6─ < 12 148 101 1.15 (0.81–1.63) 11 0.88 (0.34–2.27)
12─ < 34 70 44 0.98 (0.61–1.57) 9 1.20 (0.42–3.44)
Stage
Local 52 9 1.00 Ref. 9 1.00 Ref.
Advanced 330 256 9.05 (4.60–17.82) 19 0.80 (0.32–2.01)
Unknown 39 11 1.60 (0.66–3.89) 6 1.01 (0.32–3.23)
Pre-diagnostic statin use
No 235 162 1.00 Ref. 20 1.00 Ref.
Yes 186 114 0.72 (0.56–0.93) 14 0.66 (0.30–1.43)
Pre-diagnostic ADM group
Metformin 77 46 1.15 (0.74–1.79) 5 1.85 (0.44–7.73)
Othera 58 44 1.00 Ref. 4 1.00 Ref.
Metformin and othera 100 67 1.21 (0.82–1.80) 6 1.19 (0.32–4.38)
Insulin 82 59 1.49 (0.96–2.30) 7 1.61 (0.42–6.18)
None 104 60 0.69 (0.46–1.03) 12 1.48 (0.46–4.78)
All HRs were adjusted for the other factors in this table
aother oral antidiabetic medication
OC Ovarian cancer, HR Hazard ratio, 95% CI 95% confidence interval
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the occurrence of relapses of ovarian cancer and ovarian
cancer-related deaths [37]. In line with our findings,
Garcia et al. found no association between metformin
use and better overall survival [38]. However, the study
populations in these two investigations were not limited
to women with type 2 diabetes [37, 38].
Selection of the reference medication affects interpret-
ation of the results. In our study, the reference group for
metformin users was the group of users of other forms
of oral ADM, which is relevant when addressing the
possible influence of metformin on cancer survival in
T2D patients. Using “no antidiabetic medication” as the
reference group could lead to bias, as persons with T2D
without any proper medication would represent a select-
ive group with prognostic differences. In some previous
studies the reference groups for metformin users have
been non-users of metformin [8, 37, 38]. In a study car-
ried out by Kumar et al. [6], the reference group com-
prised non-diabetic non-metformin users and women
with diabetes who used insulin or other types of ADM.
A major strength of our study is the availability of reli-
able and comprehensive Finnish national registers. A
unique personal identification code (PIC) is used in all
registers involved. FinDM database covers whole Finland
and therefore it is an exceptional resource. Data quality
is usually considered to be high in Finnish registers, such
as, for example, the Finnish Hospital Discharge Register
[39]. The duration of diabetes is considered to be rela-
tively accurately recorded in the FinDM database, even
though there can be some minor errors connected to
diet-controlled diabetes. In Finland, all forms of ADM
and statins are prescribed by doctors and reimbursed by
the Social Insurance Institution, and therefore data on
the duration of use of medication is accurate. Also, the
Finnish Cancer Registry is recognized to have high qual-
ity with regard to completeness and accuracy, 93% of
cancer cases being microscopically verified [25].
In addition to the above, the size of our study cohort
is greater than in previous studies addressing the roles
of metformin and statins in connection with OC sur-
vival. In particular, the number of metformin users
among OC patients was relatively large in our study
compared with those in prior studies [6–8]. However,
our study population is limited to women with T2D, and
therefore the results can strictly be generalized only to
women with T2D.
Obesity has been associated with poorer ovarian can-
cer prognosis [40], and, therefore, may be an important
confounder in our study. However, our study lacked data
on BMI. Also, the FinDM database does not contain in-
formation on aspects of life style, such as smoking, alco-
hol consumption, exercise or diet, which can also have
an influence on ovarian cancer survival. Neither does
FinDM database include measures regarding the severity
of T2D, including data on HbA1c but duration of T2D
and history of insulin use can be observed as surrogate
indicators of the severity of T2D. In addition, we do not
have data on cholesterol levels of the patients, and there-
fore we cannot be sure whether the observed association
of mortality from OC with the use of statins is partly or
wholly attributable to cholesterol levels, insofar as the
latter were an independent prognostic marker of OC.
Comorbidities are not recorded in adequate complete-
ness and detail in FinDM, and therefore not included in
our study. It is known that statin use is linked to heart
diseases [13] and is thus related to mortality from causes
other than cancer. Despite our relatively large cohort,
the number of deaths from causes other than cancer was
small with the consequence that our estimation results
on this component of mortality are highly unreliable
with a wide margin of error.
The Finnish Cancer Registry also contains some infor-
mation about the treatment of cancer, but the data are
not comprehensive or complete enough and thus were
not included in our study. However, the national ovarian
cancer treatment schedule has guidelines concerning
surgery and first-line chemotherapy, and these guidelines
did not change during the study period [41].
In pharmacoepidemiological studies exposure assess-
ment can never be completely free from misclassifica-
tion. Therefore, some information bias as to the use
of drugs under study is to be expected. However, the
concordance between self-reported medication use
and information contained in the prescription register
has been shown to be good [42]. The reimbursement
connected with the costs of ADM and statins also
strengthens the reliability of our data. However, drugs
dispensed in hospitals and outpatient clinics are not
covered by the Register on Reimbursed Drug pur-
chases and therefore we lack data on medication used
by the small proportion of patients who were treated
in healthcare facilities.
Socioeconomic differences might be associated with
statin use. It has been found that in patients with lower
income, the use of statins is 10% lower compared with
the overall level [13]. In our study, data on socioeco-
nomic status was not available and therefore not ad-
justed for in our results, and this could lead to a
healthy-user bias in statin users.
Conclusion
Our findings are inconclusive as regards an association
between metformin and OC survival. However, there is
some evidence of improved prognosis of ovarian cancer
with pre-diagnostic statin use. Ovarian cancer is a rare
disease associated with high mortality, and more re-
search is needed to find new forms of medication to im-
prove its prognosis.
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confidence interval, DDD defined daily dose. (PDF 251 kb)
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